Ascendis Pharma's target audience includes patients suffering from endocrinology rare diseases and oncological conditions, healthcare professionals specializing in these areas (endocrinologists, oncologists, and other relevant specialists), and pharmaceutical companies interested in partnering or licensing Ascendis Pharma's TransCon technology-based products. The company caters to a global audience, with a focus on regions including the United States, Europe, and Greater China. The specific conditions targeted include pediatric growth hormone deficiency (GHD), adult GHD, Turner Syndrome, adult hypoparathyroidism, achondroplasia, and solid tumors. Additionally, Ascendis Pharma aims to reach investors interested in biopharmaceutical companies developing innovative therapies.